Zacks Research Brokers Raise Earnings Estimates for Haemonetics Co. (NYSE:HAE)

Haemonetics Co. (NYSE:HAE - Free Report) - Stock analysts at Zacks Research boosted their FY2027 earnings per share (EPS) estimates for Haemonetics in a research report issued to clients and investors on Thursday, September 12th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will earn $5.92 per share for the year, up from their prior forecast of $5.91. The consensus estimate for Haemonetics' current full-year earnings is $4.58 per share.

A number of other brokerages have also recently commented on HAE. JMP Securities reissued a "market outperform" rating and issued a $125.00 price target on shares of Haemonetics in a research report on Tuesday, August 13th. Barrington Research boosted their target price on Haemonetics from $107.00 to $108.00 and gave the stock an "outperform" rating in a report on Friday, August 9th. Citigroup reduced their price target on Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a report on Thursday, August 22nd. Bank of America began coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price objective on the stock. Finally, CL King began coverage on shares of Haemonetics in a research note on Friday. They issued a "buy" rating and a $116.00 target price on the stock. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $106.14.

Haemonetics Stock Up 0.8 %

NYSE:HAE traded up $0.61 during mid-day trading on Monday, hitting $76.70. 392,453 shares of the company's stock were exchanged, compared to its average volume of 534,859. Haemonetics has a one year low of $70.74 and a one year high of $97.97. The business has a fifty day moving average price of $81.20 and a 200 day moving average price of $84.05. The company has a market cap of $3.91 billion, a PE ratio of 33.49, a P/E/G ratio of 1.32 and a beta of 0.30. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.03 by ($0.01). The firm had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. Haemonetics's revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.05 EPS.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Capital Research Global Investors lifted its holdings in Haemonetics by 2.3% during the first quarter. Capital Research Global Investors now owns 6,674,751 shares of the medical instruments supplier's stock valued at $569,690,000 after purchasing an additional 151,183 shares in the last quarter. Vanguard Group Inc. increased its stake in Haemonetics by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,406,309 shares of the medical instruments supplier's stock worth $462,293,000 after buying an additional 25,451 shares in the last quarter. Wellington Management Group LLP raised its holdings in Haemonetics by 3.2% during the fourth quarter. Wellington Management Group LLP now owns 3,268,083 shares of the medical instruments supplier's stock valued at $279,454,000 after acquiring an additional 101,029 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Haemonetics by 6.3% in the second quarter. Dimensional Fund Advisors LP now owns 978,735 shares of the medical instruments supplier's stock valued at $80,972,000 after acquiring an additional 57,665 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Haemonetics by 6,573.6% in the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier's stock worth $70,267,000 after acquiring an additional 836,623 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Stewart W. Strong sold 4,312 shares of the company's stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the sale, the insider now owns 18,196 shares in the company, valued at $1,658,565.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Anila Lingamneni sold 2,136 shares of the company's stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total value of $192,240.00. Following the completion of the sale, the executive vice president now directly owns 21,410 shares in the company, valued at approximately $1,926,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Stewart W. Strong sold 4,312 shares of Haemonetics stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the transaction, the insider now owns 18,196 shares in the company, valued at $1,658,565.40. The disclosure for this sale can be found here. Insiders own 1.80% of the company's stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.